Gray-market drug scheme leads to $20M forfeiture, 30 years in slammer

A Texas man was found to have laundered more than $40 million through a fake drug distributorship that bought drugs off the street and then sold them as new. (Pixabay)

A man who made tens of millions of dollars selling gray-market drugs in the U.S. has not only been sentenced to 30 years in federal prison, he is being made to pay a $700,000 tax bill.

Kenneth J. Coleman, 52, of Houston, Texas, was sentenced to 360 months for conspiracy and tax charges, after being convicted on nine counts that included conspiracy to commit money laundering and corporate tax evasion.

The government says Coleman laundered more than $41.5 million through a fake drug distribution business. In addition to prison time, he was ordered to forfeit $20.3 million and to pay $717,000 in restitution to the IRS.

Free Amazon Webinar

Performing end to end real-world evidence generation in the cloud with traceability and transparency- a Sanofi journey

In this webinar you will hear about Sanofi’s journey and experience in building an industrialized big data & analytics platform in the cloud that handles billions of rows of RWD data with complete data traceability, security, and supports both traditional and advanced analytics for day to day evidence generation (RWE).

Coleman owned Acacia Pharma Distributors and Four Corner Suppliers, which purchased bottles of prescription medications from “illegitimate sources” and then sold them to a Utah-based distributor, which then sold them to pharmacies as new, the FDA reported. The company created fake pedigrees to disguise them.

A partner in the business, Marcus Weathersby, pleaded guilty and testified against Coleman. Weathersby was sentenced to just short of five years in prison.

Read more on

Suggested Articles

Nearly four decades after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.

Pfizer's 1.1-million-square-foot sterile injectables plant in Visakhapatnam has been criticized by the FDA for poor quality testing.

Amidst a gung-ho shift to oncology, Daiichi is also fleshing out its gene therapy capacity with a $200 million licensing deal with Ultragenyx.